Genome-wide association study of Alzheimer's disease with psychotic symptoms

Molecular Psychiatry

Volumn 17, Issue 12, 2012, Pages 1316-1327

  Hollingworth, P ^a   Sweet, R ^b,c   Sims, R ^a   Harold, D ^a   Russo, G ^a   Abraham, R ^a   Stretton, A ^a   Jones, N ^a   Gerrish, A ^a   Chapman, J ^a   Ivanov, D ^a   Moskvina, V ^a   Lovestone, S ^d   Priotsi, P ^d   Lupton, M ^d   Brayne, C ^e   Gill, M ^f   Lawlor, B ^f   Lynch, A ^f   Craig, D ^g   McGuinness, B ^g   Johnston, J ^g   Holmes, C ^h   Livingston, G ⁱ   Bass, N J ⁱ   Gurling, H ⁱ   McQuillin, A ⁱ   Holmans, P ^a   Jones, L ^a   Devlin, B ^b   Klei, L ^b   Barmada, M M ^l   Demirci, F Y ^l   Dekosky, S T ^b,l   Lopez, O L ^b   Passmore, P ^g   Owen, M J ^a   O'Donovan, M C ^a   Mayeux, R ^j   Kamboh, M I ^k   Williams, J ^a   more..

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f ST JAMES S HOSPITAL   (Ireland)

^g QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^h UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j Och Spine at New York Presbyterian Hospitals   (United States)

^k UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^l UNIVERSITY OF VIRGINIA   (United States)

more..

Author keywords

Alzheimer's disease; behavioural symptoms; genetic; genome wide associationstudy; psychosis

Indexed keywords

APOLIPOPROTEIN E;

AGED; ALZHEIMER DISEASE; ARTICLE; CHROMOSOME 4; COGNITIVE DEFECT; DISEASE ASSOCIATION; FEMALE; GENE MAPPING; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HERITABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE DEGENERATION; PRIORITY JOURNAL; PSYCHOSIS; QUALITY CONTROL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84869998396     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2011.125     Document Type: Article

References (72)

1. Hollingworth P, Harold D, Jones L, Owen MJ, Williams J. Alzheimer's disease genetics: current knowledge and future challenges. Int J Geriatr Psychiatry 2011; 26: 793-802.
2. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009; 41: 1088-1093.
3. Corneveaux JJ, Myers AJ, Allen AN, Pruzin JJ, Ramirez M, Engel A et al. Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum Mol Genet 2010; 19: 3295-3301.
4. Zhang Q, Yu JT, Zhu QX, Zhang W, Wu ZC, Miao D et al. Complement receptor 1 polymorphisms and risk of late onset Alzheimer's disease. Brain Res 2010; 1348: 216-221.
5. Carrasquillo MM, Belbin O, Hunter TA, Ma L, Bisceglio GD, Zou F et al. Replication of CLU, CR1, and PICALM associations with Alzheimer disease. Arch Neurol 2010; 67: 961-964.
6. Jun G, Naj AC, Beecham GW, Wang LS, Buros J, Gallins PJ et al. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol 2010; 67: 1473-1484.
7. Biffi A, Anderson CD, Desikan RS, Sabuncu M, Cortellini L, Schmansky N et al. Genetic variation and neuroimaging measures in Alzheimer disease. Arch Neurol 2010; 67: 677-685.
8. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010; 303: 1832-1840.
9. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM et al. Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011; 43: 429-435.
10. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 2011; 43: 436-441.
11. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ et al. Finding the missing heritability of complex diseases. Nature 2009; 461: 747-753.
12. O'Donovan MC, Craddock NJ, Owen MJ. Genetics of psychosis; insights from views across the genome. Hum Genet 2009; 126: 3-12.
13. Sweet RA, Nimgaonkar VL, Devlin B, Jeste DV. Psychotic symptoms in Alzheimer disease: evidence for a distinct phenotype. Mol Psychiatry 2003; 8: 383-392.
14. Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry 2005; 162: 2022-2030.
15. Shin IS, Carter M, Masterman D, Fairbanks L, Cummings JL. Neuropsychiatric symptoms and quality of life in Alzheimer disease. Am J Geriatr Psychiatry 2005; 13: 469-474.
16. Wilkosz PA, Seltman HJ, Devlin B, Weamer EA, Lopez OL, Dekosky ST et al. Trajectories of cognitive decline in Alzheimer's disease. Int Psychogeriatr 2010; 22: 281-290.
17. Lopez OL, Wisniewski SR, Becker JT, Boller F, DeKosky ST. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol 1999; 56: 1266-1272.
18. Hollingworth P, Hamshere ML, Holmans PA, O'Donovan MC, Sims R, Powell J et al. Increased familial risk and genomewide significant linkage for Alzheimer's disease with psychosis. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 841-848.
19. Sweet RA, Nimgaonkar VL, Devlin B, Lopez OL, DeKosky ST. Increased familial risk of the psychotic phenotype of Alzheimer disease. Neurology 2002; 58: 907-911.
20. Bacanu SA, Devlin B, Chowdari KV, DeKosky ST, Nimgaonkar VL, Sweet RA. Heritability of psychosis in Alzheimer disease. Am J Geriatr Psychiatry 2005; 13: 624-627.
21. Sweet RA, Bennett DA, Graff-Radford NR, Mayeux R. Assessment and familial aggregation of psychosis in Alzheimer's disease from the National Institute on Aging Late Onset Alzheimer's Disease Family Study. Brain 2010; 133(Part 4): 1155-1162.
22. DeMichele-Sweet MA, Sweet RA. Genetics of psychosis in Alzheimer's disease: a review. J Alzheimers Dis 2010; 19: 761-780.
23. Wijsman EM, Pankratz ND, Choi Y, Rothstein JH, Faber KM, Cheng R et al. Genome wide association of familial late onset Alzheimer's disease replicates BIN1 and CLU, and nominates CUGBP2 in interaction with APOE. PLoS Genet 2011; 7: e1001308.
24. Demichele-Sweet MA, Kleia L, Devlin B, Ferrellb RE, Weamera EA, Emanuela JE et al. No association of psychosis in Alzheimer disease with neurodegenerative pathway genes. Neurobiol Aging 2011; 32: 555.e9-555.e11.
25. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
26. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-486.
27. Lee JH, Cheng R, Graff-Radford N, Foroud T, Mayeux R. Analyses of the National Institute on Aging Late-Onset Alzheimer's Disease Family Study: implication of additional loci. Arch Neurol 2008; 65: 1518-1526.
28. Weamer EA, Emanuel JE, Varon D, Miyahara S, Wilkosz PA, Lopez OL et al. The relationship of excess cognitive impairment in MCI and early Alzheimer's disease to the subsequent emergence of psychosis. Int Psychogeriatr 2009; 21: 78-85.
29. Lopez OL, DeKosky ST. Neuropathology of Alzheimer's disease and mild cognitive impairment]. Rev Neurol 2003; 37: 155-163.
30. Ganguli M, Dodge HH, Chen P, Belle S, DeKosky ST. Ten-year incidence of dementia in a rural elderly US community population: the MoVIES Project. Neurology 2000; 54: 1109-1116.
31. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-2314.
32. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997; 48(5 Suppl 6): S10-S16.
33. Tariot PN, Mack JL, Patterson MB, Edland SD, Weiner MF, Fillenbaum G et al. The behavior rating scale for dementia of the consortium to establish a registry for Alzheimer's disease. The behavioral pathology committee of the consortium to establish a registry for Alzheimer's disease. Am J Psychiatry 1995; 152: 1349-1357.
34. Wilkosz PA, Kodavali C, Weamer EA, Miyahara S, Lopez OL, Nimgaonkar VL et al. Prediction of psychosis onset in Alzheimer disease: the role of depression symptom severity and the HTR2A T102C polymorphism. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 1054-1062.
35. Hollingworth P, Hamshere ML, Moskvina V, Dowzell K, Moore PJ, Foy C et al. Four components describe behavioral symptoms in 1,120 individuals with late-onset Alzheimer's disease. J Am Geriatr Soc 2006; 54: 1348-1354.
36. Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139: 1136-1139.
37. Berg L. Clinical Dementia Rating (CDR). Psychopharmacol Bull 1988; 24: 637-639.
38. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
39. Kamboh MI, Barmada MM, Demirci FY, Minster RL, Carrasquillo MM, Pankratz VS et al. Genome-wide association analysis of ageat-onset in Alzheimer's disease. Mol Psychiatry 2011 (in press).
40. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904-909.
41. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
42. Lee AB, Luca D, Klei L, Devlin B, Roeder K. Discovering genetic ancestry using spectral graph theory. Genet Epidemiol 2010; 34: 51-59.
43. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient metaanalysis of genomewide association scans. Bioinformatics 2010; 26: 2190-2191.
44. Devlin B, Roeder K. Genomic control for association studies. Biometrics 1999; 55: 997-1004.
45. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009; 41: 1094-1099.
46. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D et al. Common variants conferring risk of schizophrenia. Nature 2009; 460: 744-747.
47. O'Donovan MC, Craddock N, Norton N, Williams H, Peirce T, Moskvina V et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet 2008; 40: 1053-1055.
48. Ferreira MA, O'Donovan MC, Meng YA, Jones IR, Ruderfer DM, Jones L et al. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet 2008; 40: 1056-1058.
49. McMahon FJ, Akula N, Schulze TG, Muglia P, Tozzi F, Detera-Wadleigh SD et al. Meta-analysis of genome-wide association data identifies a risk locus for major mood disorders on 3p21.1. Nat Genet 2010; 42: 128-131.
50. Cichon S, Muhleisen TW, Degenhardt FA, Mattheisen M, Miro X, Strohmaier J et al. Genome-wide association study identifies genetic variation in neurocan as a susceptibility factor for bipolar disorder. Am J Hum Genet 2011; 88: 372-381.
51. Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe'er I et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009; 460: 753-757.
52. Whitlock MC. Combining probability from independent tests: the weighted Z-method is superior to Fisher's approach. J Evol Biol 2005; 18: 1368-1373.
53. Braunewell KH, Klein-Szanto AJ. Visinin-like proteins (VSNLs): interaction partners and emerging functions in signal transduction of a subfamily of neuronal Ca2\+-sensor proteins. Cell Tissue Res 2009; 335: 301-316.
54. Lee JM, Blennow K, Andreasen N, Laterza O, Modur V, Olander J et al. The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin Chem 2008; 54: 1617-1623.
55. Beveridge NJ, Tooney PA, Carroll AP, Gardiner E, Bowden N, Scott RJ et al. Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum Mol Genet 2008; 17: 1156-1168.
56. Martins-de-Souza D, Gattaz WF, Schmitt A, Rewerts C, Marangoni S, Novello JC et al. Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. J Neural Transm 2009; 116: 275-289.
57. Rule AD, de Andrade M, Matsumoto M, Mosley TH, Kardia S, Turner ST. Association between SLC2A9 transporter gene variants and uric acid phenotypes in African American and white families. Rheumatology (Oxford) 2011; 50: 871-878.
58. Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CN et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008; 40: 437-442.
59. Bowman GL, Shannon J, Frei B, Kaye JA, Quinn JF. Uric acid as a CNS antioxidant. J Alzheimers Dis 2010; 19: 1331-1336.
60. Yao JK, Reddy R, van Kammen DP. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res 1998; 80: 29-39.
61. Reddy R, Keshavan M, Yao JK. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res 2003; 62: 205-212.
62. Kam M, Massare J, Gallinger S, Kinzie J, Weaver D, Dingell JD et al. Peutz-Jeghers syndrome diagnosed in a schizophrenic patient with a large deletion in the STK11 gene. Dig Dis Sci 2006; 51: 1567-1570.
63. Lee CH, Liu CM, Wen CC, Chang SM, Hwu HG. Genetic copy number variants in sib pairs both affected with schizophrenia. J Biomed Sci 2010; 17: 2.
64. Demichele-Sweet MA, Lopez OL, Sweet RA. Psychosis in Alzheimer's disease in the national Alzheimer's disease coordinating center uniform data set: clinical correlates and association with apolipoprotein e. Int J Alzheimers Dis 2011; 2011: 926597.
65. Chu SH, Roeder K, Ferrell RE, Devlin B, DeMichele-Sweet MA, Kamboh MI et al. TOMM40 poly-T repeat lengths, age of onset and psychosis risk in Alzheimer disease. Neurobiol Aging 2011 (in press).
66. Lichtenstein P, Yip BH, Bjork C, Pawitan Y, Cannon TD, Sullivan PF et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 2009; 373: 234-239.
67. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009; 460: 748-752.
68. Lettre G, Rioux JD. Autoimmune diseases: insights from genome-wide association studies. Hum Mol Genet 2008; 17(R2): R116-R121.
69. Craddock N, O'Donovan MC, Owen MJ. Psychosis genetics: modeling the relationship between schizophrenia, bipolar disorder, and mixed (or "schizoaffective") psychoses. Schizophr Bull 2009; 35: 482-490.
70. Moskvina V, Holmans P, Schmidt KM, Craddock N. Design of casecontrols studies with unscreened controls. Ann Hum Genet 2005; 69(Part 5): 566-576.
71. Kamboh MI, Minster RL, Demirci FY, Ganguli M, Dekosky ST, Lopez OL et al. Association of CLU and PICALM variants with Alzheimer's disease. Neurobiol Aging 2010 (in press).
72. Schjeide BM, Schnack C, Lambert JC, Lill CM, Kirchheiner J, Tumani H et al. The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels. Arch Gen Psychiatry 2011; 68: 207-213.